Are you Dr. Dubow?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 53 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
257 Lafayette Ave
Suite 330
Suffern, NY 10901Phone+1 845-368-8808Fax+1 845-368-5608
Summary
- Dr. Jordan Dubow, MD is a board certified neurologist in Suffern, New York. He is currently licensed to practice medicine in New York, Michigan, and Illinois.
Education & Training
New York Presbyterian Hospital (Cornell Campus)Fellowship, Vascular Neurology, 2010 - 2011
UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Internal Medicine, 2003 - 2006
Northwestern University The Feinberg School of MedicineClass of 2003
Certifications & Licensure
IL State Medical License 2007 - 2026
MI State Medical License 2011 - 2012
NY State Medical License 2009 - 2011- American Board of Psychiatry and Neurology Neurology
Publications & Presentations
PubMed
- 8 citationsPharmacokinetics of FT218, a Once-Nightly Sodium Oxybate Formulation in Healthy Adults.David Seiden, Charles Tyler, Jordan Dubow
Clinical Therapeutics. 2021-02-23 - 104 citationsEfficacy and safety of deflazacort vs prednisone and placebo for Duchenne muscular dystrophyRobert C. Griggs, J. Phillip Miller, Cheryl R. Greenberg, Darcy Fehlings, Alan Pestronk
Neurology. 2016-11-15 - 57 citationsSublingual apomorphine (APL-130277) for the acute conversion of OFF to ON in Parkinson's disease.Robert A. Hauser, C. Warren Olanow, Bruce Dzyngel, Thierry Bilbault, Holly A. Shill
Movement Disorders. 2016-09-01
Press Mentions
Paragon Biosciences' CEO Jeff Aronin Names Jordan Dubow New Chief Medical OfficerApril 15th, 2021- Illinois Bill Would Make Telehealth Payment Parity Permanent • Community First Nurses Demand Safety Protections Following Federal Investigation • Medical College Nears AccreditationFebruary 24th, 2021
Avadel Pharmaceuticals Announces Positive Topline Results from Its Pivotal Phase 3 REST-ON Trial of Once-Nightly FT218 for the Treatment of Excessive Daytime Sleepiness and Cataplexy in Patients with NarcolepsyApril 27th, 2020- Join now to see all
